Metastatic melanoma after solid organ transplantation: An interdisciplinary, institution-based review of management with systemic and targeted therapies

To the Editor: Invasive melanoma incidence is over 2-fold increased among organ transplant recipients (OTRs) compared to the general population; OTRs also have a 3-fold increased risk for disease-specific mortality compared with the general population.1 Recent advances in the treatment of metastatic melanoma, including targeted therapies (BRAF and MEK inhibitors) and checkpoint inhibitors (anti –cytotoxic T-lymphocyte–associated protein [CTLA] 4 and anti–programmed cell death [PD] 1) have revolutionized melanoma treatment and had a major impact on progression-free and overall survival for the general population.

Source: Journal of the American Academy of Dermatology - December 12, 2017 Category: Dermatology Authors: Shivani V. Tripathi, Caroline R. Morris, Tarek Alhamad, Ryan C. Fields, Gerald P. Linette, Lynn A. Cornelius Tags: Research letter Source Type: research